Benitec Biopharma Ltd ADR (BNTC)

$13.63 +0.75 (5.82%)
Market Cap 442.48M
Revenue (ttm) 0.00
Net Income (ttm) -37.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 192,400
Avg Vol 98,682
Day's Range N/A - N/A
Shares Out 34.35M
Stochastic %K 89%
Beta 0.27
Analysts Strong Sell
Price Target $25.80

Company Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene thera...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 780 0819
Website: benitec.com
Address:
3940 Trust Way, Hayward, United States
SuperGreenToday
SuperGreenToday Jun. 10 at 8:31 PM
$BNTC Share Price: $10.40 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.71 – $0.87 Potential Upside: 57% ROI Time to Expiration: 127 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
focafoca99
focafoca99 May. 14 at 12:32 PM
$BNTC released its fiscal quarter ended March 31, 2026 results and operational update.
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 28 at 12:34 PM
$BNTC (+2.2% pre) Benitec Biopharma to present BB-301 clinical data at gene therapy meeting https://ooc.bz/l/100204
0 · Reply
XCo
XCo Mar. 24 at 7:52 AM
$BNTC any other bitcoin big project stock?
0 · Reply
topstockalerts
topstockalerts Mar. 9 at 4:06 PM
$BNTC Spec biotech that tends to react sharply to volume shifts. Recently showing stabilization after volatility. If it breaks resistance, fast momentum entries usually follow.
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 9 at 12:21 PM
$BNTC (+5.8% pre) Benitec reports positive interim results for OPMD gene therapy BB-301 https://ooc.bz/l/95947
0 · Reply
DARKP00L
DARKP00L Mar. 9 at 11:39 AM
$BNTC 07:13 on Mar. 09 2026 Benitec Biopharma Announced Promising Interim Clinical Results From The BB-301 Phase 1b/2a First-in-human Study (NCT06185673) Evaluating Low Dose And High Dose BB-301 Treatment For Oculopharyngeal Muscular Dystrophy With Moderate Dysphagia #tradeideas
0 · Reply
DekmarTrades
DekmarTrades Mar. 9 at 11:05 AM
$BNTC Announces Positive Interim Phase 1b/2a
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 3:31 PM
$BNTC Current Stock Price: $10.47 Contracts to trade: $12.5 BNTC Feb 20 2026 Call Entry: $0.72 Exit: $1.36 ROI: 88% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Peter1735
Peter1735 Feb. 18 at 8:09 PM
$BNTC touched 11.55 and dumped all the way down.
0 · Reply
Latest News on BNTC
Guggenheim downgrades Benitec to Neutral, terminates coverage

2026-06-10T11:10:28.000Z - 14 days ago

Guggenheim downgrades Benitec to Neutral, terminates coverage

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim

2026-06-10T10:56:27.000Z - 15 days ago

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

May 14, 2026, 8:00 AM EDT - 5 weeks ago

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma Earnings release: Q3 2026

May 14, 2026, 8:00 AM EDT - 5 weeks ago

Benitec Biopharma Earnings release: Q3 2026

Benitec Biopharma Quarterly report: Q3 2026

May 14, 2026, 8:00 AM EDT - 5 weeks ago

Benitec Biopharma Quarterly report: Q3 2026

Benitec Biopharma initiated with an Outperform at Evercore ISI

2026-05-12T15:53:15.000Z - 6 weeks ago

Benitec Biopharma initiated with an Outperform at Evercore ISI

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Apr 28, 2026, 7:00 AM EDT - 2 months ago

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

Mar 10, 2026, 7:00 AM EDT - 3 months ago

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

Benitec Biopharma announces interim Phase 1b/2a study of BB-301

2026-03-09T11:15:08.000Z - 3 months ago

Benitec Biopharma announces interim Phase 1b/2a study of BB-301

Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year

2026-02-12T13:36:30.000Z - 4 months ago

Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year

Benitec Biopharma Earnings release: Q2 2026

Feb 12, 2026, 8:00 AM EST - 4 months ago

Benitec Biopharma Earnings release: Q2 2026

Benitec Biopharma Quarterly report: Q2 2026

Feb 12, 2026, 8:00 AM EST - 4 months ago

Benitec Biopharma Quarterly report: Q2 2026

Benitec Biopharma files to sell 1.48M shares of common stock for holders

2026-01-30T21:05:17.000Z - 5 months ago

Benitec Biopharma files to sell 1.48M shares of common stock for holders

Benitec Biopharma Registration statement: Registration Filing

Jan 30, 2026, 7:00 AM EST - 5 months ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma first patient treated in Cohort 1 of BB-301 Phase 1b/2a study

2026-01-11T19:25:05.000Z - 5 months ago

Benitec Biopharma first patient treated in Cohort 1 of BB-301 Phase 1b/2a study

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Jan 11, 2026, 8:00 AM EST - 5 months ago

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Benitec Biopharma Slides: Corporate presentation

Jan 9, 2026, 7:00 AM EST - 5 months ago

Benitec Biopharma Slides: Corporate presentation

Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright

2025-11-24T11:22:11.000Z - 7 months ago

Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright

Benitec Biopharma reports Q1 EPS (22c), consensus (33c)

2025-11-14T22:10:41.000Z - 7 months ago

Benitec Biopharma reports Q1 EPS (22c), consensus (33c)

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

Nov 14, 2025, 5:00 PM EST - 7 months ago

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma Earnings release: Q1 2026

Nov 14, 2025, 4:00 PM EST - 7 months ago

Benitec Biopharma Earnings release: Q1 2026

Benitec Biopharma Quarterly report: Q1 2026

Nov 14, 2025, 4:00 PM EST - 7 months ago

Benitec Biopharma Quarterly report: Q1 2026

Benitec Biopharma Proxy statement: Proxy Filing

Nov 12, 2025, 7:00 AM EST - 8 months ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma $100M share Spot Secondary priced at $13.50

2025-11-06T11:21:42.000Z - 8 months ago

Benitec Biopharma $100M share Spot Secondary priced at $13.50

Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

Nov 6, 2025, 12:19 AM EST - 8 months ago

Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

Benitec Biopharma announces common stock offering, no amount given

2025-11-05T21:45:37.000Z - 8 months ago

Benitec Biopharma announces common stock offering, no amount given

Benitec Biopharma Inc. Announces Proposed Public Offering

Nov 5, 2025, 4:43 PM EST - 8 months ago

Benitec Biopharma Inc. Announces Proposed Public Offering

Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright

2025-11-04T17:35:25.000Z - 8 months ago

Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright

Benitec Biopharma price target raised to $22 from $20 at Citizens JMP

2025-11-04T10:45:27.000Z - 8 months ago

Benitec Biopharma price target raised to $22 from $20 at Citizens JMP

Benitec provide interim clinical results for BB-301 Phase 1b/2a trial of BB-301

2025-11-03T12:15:58.000Z - 8 months ago

Benitec provide interim clinical results for BB-301 Phase 1b/2a trial of BB-301

Benitec Biopharma appoints Mates to board of directors

2025-11-03T12:15:33.000Z - 8 months ago

Benitec Biopharma appoints Mates to board of directors

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Nov 3, 2025, 7:10 AM EST - 8 months ago

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

Nov 2, 2025, 7:00 PM EST - 8 months ago

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

Benitec Biopharma Proxy statement: Proxy Filing

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Proxy statement: Proxy Filing

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma files $200M mixed securities shelf

2025-09-22T21:20:13.000Z - 9 months ago

Benitec Biopharma files $200M mixed securities shelf

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

Sep 22, 2025, 4:05 PM EDT - 9 months ago

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

Benitec Biopharma Earnings release: Q4 2025

Sep 22, 2025, 9:30 AM EDT - 9 months ago

Benitec Biopharma Earnings release: Q4 2025

Benitec Biopharma Annual report: Q4 2025

Sep 22, 2025, 9:30 AM EDT - 9 months ago

Benitec Biopharma Annual report: Q4 2025

Benitec Biopharma Registration statement: Registration Filing

Sep 22, 2025, 8:00 AM EDT - 9 months ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma price target lowered to $29 from $35 at Oppenheimer

2025-09-16T12:10:25.000Z - 10 months ago

Benitec Biopharma price target lowered to $29 from $35 at Oppenheimer

Benitec Biopharma management to meet with Piper Sandler

2025-09-05T11:05:13.000Z - 10 months ago

Benitec Biopharma management to meet with Piper Sandler

Benitec Biopharma Slides: Corporate presentation

Sep 4, 2025, 7:00 AM EDT - 10 months ago

Benitec Biopharma Slides: Corporate presentation

Benitec Biopharma Registration statement: Registration Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Quarterly report: Q3 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Benitec Biopharma Quarterly report: Q3 2025

Benitec Biopharma Earnings release: Q3 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Benitec Biopharma Earnings release: Q3 2025

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

Benitec Biopharma Slides: Study Update

Mar 18, 2025, 7:00 PM EDT - 1 year ago

Benitec Biopharma Slides: Study Update

Benitec Biopharma Slides: Corporate Presentation

Mar 5, 2025, 4:00 PM EST - 1 year ago

Benitec Biopharma Slides: Corporate Presentation

Benitec Biopharma Quarterly report: Q2 2025

Feb 14, 2025, 4:00 PM EST - 1 year ago

Benitec Biopharma Quarterly report: Q2 2025

Benitec Biopharma Earnings release: Q2 2025

Feb 14, 2025, 4:00 PM EST - 1 year ago

Benitec Biopharma Earnings release: Q2 2025

Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

Feb 14, 2025, 8:10 AM EST - 1 year ago

Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

Benitec Biopharma to Participate in Upcoming Investor Conferences in December

Nov 26, 2024, 7:00 AM EST - 1 year ago

Benitec Biopharma to Participate in Upcoming Investor Conferences in December

Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

Nov 14, 2024, 4:30 PM EST - 1 year ago

Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

Benitec Biopharma Quarterly report: Q1 2025

Nov 14, 2024, 4:00 PM EST - 1 year ago

Benitec Biopharma Quarterly report: Q1 2025

Benitec Biopharma Earnings release: Q1 2025

Nov 14, 2024, 4:00 PM EST - 1 year ago

Benitec Biopharma Earnings release: Q1 2025

Benitec Biopharma Proxy statement: Proxy Filing

Nov 14, 2024, 7:00 AM EST - 1 year ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

Nov 4, 2024, 8:00 AM EST - 1 year ago

Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

Benitec Biopharma Registration statement: Registration Filing

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Proxy statement: Proxy Filing

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Proxy statement: Proxy Filing

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Announces Updated Investor Webcast Information

Oct 14, 2024, 6:00 AM EDT - 1 year ago

Benitec Biopharma Announces Updated Investor Webcast Information

Benitec Biopharma Slides: Study Result

Oct 13, 2024, 6:00 PM EDT - 1 year ago

Benitec Biopharma Slides: Study Result

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Oct 12, 2024, 6:30 AM EDT - 1 year ago

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Benitec Biopharma Proxy statement: Proxy Filing

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Sep 26, 2024, 4:30 PM EDT - 1 year ago

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Benitec Biopharma Annual report: Q4 2024

Sep 26, 2024, 4:00 PM EDT - 1 year ago

Benitec Biopharma Annual report: Q4 2024

Benitec Biopharma Earnings release: Q4 2024

Sep 26, 2024, 4:00 PM EDT - 1 year ago

Benitec Biopharma Earnings release: Q4 2024

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

Benitec Biopharma Proxy statement: Proxy Filing

Jul 29, 2024, 8:00 AM EDT - 2 years ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Proxy statement: Proxy Filing

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study

Jul 15, 2024, 6:00 AM EDT - 2 years ago

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study

Benitec Biopharma Registration statement: Registration Filing

May 16, 2024, 8:00 AM EDT - 2 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Quarterly report: Q3 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Benitec Biopharma Quarterly report: Q3 2024

Benitec Biopharma Earnings release: Q3 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Benitec Biopharma Earnings release: Q3 2024

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update

May 13, 2024, 8:15 AM EDT - 2 years ago

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update

Benitec Biopharma Slides: FY 2024

Apr 18, 2024, 4:00 PM EDT - 2 years ago

Benitec Biopharma Slides: FY 2024

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

Apr 18, 2024, 7:30 AM EDT - 2 years ago

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

Apr 18, 2024, 7:00 AM EDT - 2 years ago

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

Benitec Biopharma Registration statement: Registration Filing

Feb 23, 2024, 7:00 AM EST - 2 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Quarterly report: Q2 2024

Feb 13, 2024, 4:00 PM EST - 2 years ago

Benitec Biopharma Quarterly report: Q2 2024

Benitec Biopharma Earnings release: Q2 2024

Feb 13, 2024, 4:00 PM EST - 2 years ago

Benitec Biopharma Earnings release: Q2 2024

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

Feb 13, 2024, 8:00 AM EST - 2 years ago

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

Benitec Biopharma Slides: Corporate Presentation

Jan 6, 2024, 4:00 PM EST - 2 years ago

Benitec Biopharma Slides: Corporate Presentation

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Nov 30, 2023, 7:00 AM EST - 2 years ago

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

Nov 17, 2023, 8:00 AM EST - 2 years ago

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

Benitec Biopharma Quarterly report: Q1 2024

Nov 13, 2023, 4:00 PM EST - 2 years ago

Benitec Biopharma Quarterly report: Q1 2024

Benitec Biopharma Earnings release: Q1 2024

Nov 13, 2023, 4:00 PM EST - 2 years ago

Benitec Biopharma Earnings release: Q1 2024

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

Nov 13, 2023, 8:00 AM EST - 2 years ago

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

Benitec Biopharma Proxy statement: Proxy Filing

Oct 20, 2023, 8:00 AM EDT - 2 years ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Proxy statement: Proxy Filing

Oct 20, 2023, 8:00 AM EDT - 2 years ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

Aug 11, 2023, 1:00 PM EDT - 3 years ago

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

Aug 8, 2023, 10:30 PM EDT - 3 years ago

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

Benitec Biopharma Registration statement: Registration Filing

Aug 7, 2023, 8:00 AM EDT - 3 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Registration statement: Registration Filing

Aug 3, 2023, 8:00 AM EDT - 3 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Registration statement: Registration Filing

Jul 31, 2023, 8:00 AM EDT - 3 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023

Jul 25, 2023, 1:00 PM EDT - 3 years ago

Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023

Benitec Biopharma Registration statement: Registration Filing

Jul 7, 2023, 8:00 AM EDT - 3 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Slides: Corporate presentation

Jul 7, 2023, 6:00 AM EDT - 3 years ago

Benitec Biopharma Slides: Corporate presentation

Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Jun 26, 2023, 8:00 AM EDT - 3 years ago

Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

May 15, 2023, 8:00 AM EDT - 3 years ago

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

Benitec Biopharma to Present at the OPMD International Conference

May 8, 2023, 8:05 AM EDT - 3 years ago

Benitec Biopharma to Present at the OPMD International Conference

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

Feb 13, 2023, 8:00 AM EST - 3 years ago

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Jan 23, 2023, 9:48 AM EST - 3 years ago

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Benitec Biopharma Slides: Corporate presentation

Jan 5, 2023, 6:00 AM EST - 3 years ago

Benitec Biopharma Slides: Corporate presentation

Benitec Biopharma Registration statement: Registration Filing

Dec 13, 2022, 7:00 AM EST - 3 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

Nov 10, 2022, 8:00 AM EST - 3 years ago

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

Benitec Biopharma Proxy statement: Proxy Filing

Oct 25, 2022, 8:00 AM EDT - 3 years ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Proxy statement: Proxy Filing

Oct 25, 2022, 8:00 AM EDT - 3 years ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Proxy statement: Proxy Filing

Oct 14, 2022, 8:00 AM EDT - 4 years ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

Sep 16, 2022, 8:42 AM EDT - 4 years ago

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

Sep 12, 2022, 10:06 PM EDT - 4 years ago

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

Benitec Biopharma Registration statement: Registration Filing

Sep 12, 2022, 8:00 AM EDT - 4 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Registration statement: Registration Filing

Sep 9, 2022, 8:00 AM EDT - 4 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

Sep 2, 2022, 8:00 AM EDT - 4 years ago

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

Benitec Biopharma Registration statement: Registration Filing

Aug 10, 2022, 8:00 AM EDT - 4 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Registration statement: Registration Filing

Aug 8, 2022, 8:00 AM EDT - 4 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Registration statement: Registration Filing

Jul 29, 2022, 8:00 AM EDT - 4 years ago

Benitec Biopharma Registration statement: Registration Filing

Benitec Biopharma Slides: Corporate presentation

Jun 28, 2022, 6:00 AM EDT - 4 years ago

Benitec Biopharma Slides: Corporate presentation

Benitec Biopharma Releases Q3 2022 Financial Results

May 16, 2022, 8:15 AM EDT - 4 years ago

Benitec Biopharma Releases Q3 2022 Financial Results

Benitec Biopharma Discloses Q2 2022 Financial Results

Feb 14, 2022, 8:00 AM EST - 4 years ago

Benitec Biopharma Discloses Q2 2022 Financial Results

Benitec Biopharma Discloses Q1 2022 Financial Results

Nov 15, 2021, 8:00 AM EST - 5 years ago

Benitec Biopharma Discloses Q1 2022 Financial Results

Benitec Biopharma Proxy statement: Proxy Filing

Oct 22, 2021, 8:00 AM EDT - 5 years ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Proxy statement: Proxy Filing

Oct 12, 2021, 8:00 AM EDT - 5 years ago

Benitec Biopharma Proxy statement: Proxy Filing

Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results

Sep 20, 2021, 8:00 AM EDT - 5 years ago

Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results

Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

Sep 13, 2021, 3:58 PM EDT - 5 years ago

Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022

Sep 8, 2021, 8:10 AM EDT - 5 years ago

Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022

Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals

Sep 8, 2021, 8:05 AM EDT - 5 years ago

Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals

Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022

Sep 8, 2021, 8:00 AM EDT - 5 years ago

Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022

Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million

Apr 27, 2021, 9:55 PM EDT - 5 years ago

Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million

Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock

Apr 27, 2021, 4:44 PM EDT - 5 years ago

Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock

SuperGreenToday
SuperGreenToday Jun. 10 at 8:31 PM
$BNTC Share Price: $10.40 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.71 – $0.87 Potential Upside: 57% ROI Time to Expiration: 127 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
focafoca99
focafoca99 May. 14 at 12:32 PM
$BNTC released its fiscal quarter ended March 31, 2026 results and operational update.
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 28 at 12:34 PM
$BNTC (+2.2% pre) Benitec Biopharma to present BB-301 clinical data at gene therapy meeting https://ooc.bz/l/100204
0 · Reply
XCo
XCo Mar. 24 at 7:52 AM
$BNTC any other bitcoin big project stock?
0 · Reply
topstockalerts
topstockalerts Mar. 9 at 4:06 PM
$BNTC Spec biotech that tends to react sharply to volume shifts. Recently showing stabilization after volatility. If it breaks resistance, fast momentum entries usually follow.
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 9 at 12:21 PM
$BNTC (+5.8% pre) Benitec reports positive interim results for OPMD gene therapy BB-301 https://ooc.bz/l/95947
0 · Reply
DARKP00L
DARKP00L Mar. 9 at 11:39 AM
$BNTC 07:13 on Mar. 09 2026 Benitec Biopharma Announced Promising Interim Clinical Results From The BB-301 Phase 1b/2a First-in-human Study (NCT06185673) Evaluating Low Dose And High Dose BB-301 Treatment For Oculopharyngeal Muscular Dystrophy With Moderate Dysphagia #tradeideas
0 · Reply
DekmarTrades
DekmarTrades Mar. 9 at 11:05 AM
$BNTC Announces Positive Interim Phase 1b/2a
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 3:31 PM
$BNTC Current Stock Price: $10.47 Contracts to trade: $12.5 BNTC Feb 20 2026 Call Entry: $0.72 Exit: $1.36 ROI: 88% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Peter1735
Peter1735 Feb. 18 at 8:09 PM
$BNTC touched 11.55 and dumped all the way down.
0 · Reply
PatternCrawler
PatternCrawler Feb. 18 at 10:07 AM
$BNTC Immuno-oncology biotech with early-stage upside and high uncertainty.
0 · Reply
justiceforb_85
justiceforb_85 Feb. 13 at 9:48 PM
$BNTC added. Look forward to future updates.
1 · Reply
DoloresLusk827
DoloresLusk827 Feb. 11 at 4:52 PM
$BNTC Benitec Biopharma; gene therapy biotech; early-stage, high-risk; binary catalyst.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 22 at 4:50 PM
$BNTC Share Price: $12.68 Contract Selected: Jul 17, 2026 $12.5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.68 – $0.83 Potential Upside: 50% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Peter1735
Peter1735 Jan. 12 at 2:42 PM
$BNTC I don't get it.
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 1:56 PM
Pre Market Top Gainers $AKTS $EVTV $PASW $INBS $BNTC
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 12 at 1:53 PM
$BNTC (+26.7% pre) Benitec Biopharma (BNTC) Reports Promising Results from BB-301 Study https://ooc.bz/l/89373
0 · Reply